In this article, we will discuss the 10 Most Profitable Undervalued Stocks to Invest In.

On June 18, Kelsey Berro, JPMorgan Asset Management Fixed Income Portfolio Manager, appeared on CNBC’s ‘Squawk Box’ to explain the market’s reaction to the Fed’s recent monetary policy decisions and the emergence of a new leadership regime under Chair Kevin Warsh. Berro noted that the bond market responded to the press conference with a significant move higher in the front end of the yield curve, even though the market had already priced in a rate hike. Conversely, the long end of the yield curve, specifically the 30-year yield, moved lower. She interpreted this as a sign that the market trusts the Fed’s credibility in fighting inflation, particularly as five-year inflation expectations have declined to levels below where they were at the start of the conflict in the Middle East. She emphasized that the bond market prefers a Fed that acts decisively rather than one that falls behind the curve as it did in 2022, which forced more aggressive hiking.

Regarding the new leadership, Berro noted that Warsh’s primary focus is clearly price stability, a stance consistent with his history and his association with figures like Stan Druckenmiller, who view price stability as the central bank’s sole mandate. During his press conference, Warsh avoided providing forward guidance and notably did not submit a dot to the Fed’s dot plot, making him a mystery on the committee where the other members are evenly split between hiking, holding, or cutting rates. However, Berro highlighted several Easter eggs from his comments, specifically his description of a cruel trade-off. Warsh does not believe the Fed must choose between fighting inflation and weakening the labor market. She suggested that if May marked the peak for inflation and if labor market growth moderates, the Fed might avoid further hikes.

Our Methodology

We used screeners to identify stocks trading below a forward P/E of 15 that have grown revenue by at least 20% over the past 3 years and have reported high TTM net income (at least $500 million) and TTM net income margin (at least 15%). We then limited our final selection to companies that have recently reported noteworthy developments likely to impact investor sentiment. These stocks are also popular among analysts and elite hedge funds. The stocks are ranked in ascending order of their net income.

Note: All data was sourced on June 19. 

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Insider Monkey’s quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 599.2% since May 2014, beating its benchmark by 372 percentage points (see more details here).

10 Most Profitable Undervalued Stocks to Invest In

10. Innoviva Inc. (NASDAQ:INVA)

TTM Net Income: $504 million

Innoviva Inc. (NASDAQ:INVA) is one of the most profitable undervalued stocks to invest in. On June 16, Innoviva Specialty Therapeutics entered an exclusive licensing and distribution agreement with Dr. Reddy’s Laboratories to bring XACDURO to South and Central America, the Caribbean, Russia, and the CIS region. The partnership aims to address a critical health challenge, as carbapenem-resistant Acinetobacter infection rates in these areas exceed 70%.

Under the deal, Dr. Reddy’s will manage the development, regulatory approval, and commercialization of the antibiotic within these territories. Innoviva retains rights in all other regions and is set to receive an upfront payment, along with milestone payments and tiered royalties based on future net sales.

XACDURO, which is FDA-approved for treating hospital-acquired and ventilator-associated bacterial pneumonia caused by Acinetobacter, is considered a vital tool against this “critical threat” pathogen. By using Dr. Reddy’s regional expertise, Innoviva Inc. (NASDAQ:INVA) intends to broaden global access to this specialized treatment while maintaining its strategic focus.

Innoviva Inc. (NASDAQ:INVA) is a diversified holding company that manages a portfolio of biopharmaceutical royalties and invests in, develops, and commercializes healthcare assets. Its core business focuses on royalties from respiratory products (RELVAR/BREO and ANORO ELLIPTA) partnered with GSK, alongside a specialized therapeutic platform, Innoviva Specialty Therapeutics, focused on critical care and infectious diseases.

9. UMB Financial Corporation (NASDAQ:UMBF)

TTM Net Income: $882 million

UMB Financial Corporation (NASDAQ:UMBF) is one of the most profitable undervalued stocks to invest in. On May 11, UMB Bank’s Institutional Custody division reached $250 billion in assets under custody as of March 31, marking a 19% year-over-year increase. Since becoming a standalone business in 2019, the division has experienced significant growth of 298%, driven by increased demand from municipal governments, insurance providers, and asset managers for specialized middle-office services.

Growth is fueled by the rising complexity of institutional portfolios, which now require advanced solutions like collateral management, risk monitoring, and treasury support. UMB has responded by expanding its service offerings, including new foreign exchange capabilities, collective investment trustee services, and integrated liquidity solutions such as committed reverse repo facilities and lines of credit.

The division’s success is highlighted by major partnerships, including providing custodial services for the City of Fort Worth and integrating custody and credit facilities for ReFlow Fund, LLC. Led by Amy Small, the team continues to invest in technology and process automation to maintain its momentum and adapt to the evolving needs of its institutional client base.

UMB Financial Corporation (NASDAQ:UMBF) is a financial services company, offering commercial banking, personal banking, and institutional banking products and services. The company serves business clients nationwide in the US and institutional clients in several countries.